Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
Go back to Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan| AERIE PHARMACEUT (NASDAQ: AERI) | Delayed: 15.25 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.25 | 52 Week High | $41.72 | |||
| Open | $56.60 | 52 Week Low | $10.82 | |||
| Day High | $15.25 | P/E | N/A | |||
| Day Low | $15.25 | EPS | $-0.95 | |||
| Volume | 446,048 | |||||
